Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents

Area of Science:

• Oncology
• Clinical Trial Design
• Pharmacology

Background:

• Traditional dose-finding trials for chemotherapy focus solely on toxicity to determine the maximum tolerated dose (MTD).
• This MTD assumption, that the highest safe dose is most effective, is often invalid for molecularly targeted agents.
• Targeted agents may exhibit minimal toxicity across doses and dose-response relationships for efficacy can be non-linear.

Purpose of the Study:

• To propose a novel dose-finding methodology for early-phase clinical trials of molecularly targeted agents.
• To address the limitations of traditional MTD-based designs in the context of targeted therapies.
• To provide a flexible and effective approach for identifying optimal doses for novel targeted drugs.

Main Methods:

• Development of a new statistical model for early-phase dose-finding studies.
• Simulation-based evaluation of the proposed design's operating characteristics.
• Comparison with traditional dose-finding methods under various scenarios relevant to targeted agents.

Main Results:

• The proposed method demonstrates favorable operating characteristics in simulations.
• The design effectively navigates scenarios with low toxicity and non-linear dose-efficacy relationships.
• Simulation results illustrate the practical application and performance of the novel approach.

Conclusions:

• The proposed dose-finding method offers a viable alternative to traditional approaches for targeted agents.
• This new design enhances the ability to identify doses with optimal efficacy and acceptable toxicity.
• Further investigation and application in clinical settings are warranted to validate the proposed methodology.